Sub menu

 

 

Novartis Pharmaceuticals Australia Pty Ltd

Regulatory activities for this sponsor.

Type

Date

580 result(s) found, displaying 1 to 10

  • Tabrecta

    Australian public assessment report (AusPar)
    Tabrecta (capmatinib) has been approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation.

  • Tabrecta (capmatinib)

    Prescription medicine decision summary
    Tabrecta has been approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation. Tabrecta contains the active ingredient capmatinib.

  • Rhapsido

    Australian public assessment report (AusPar)
    Rhapsido (remibrutinib) has been approved for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.

  • Rhapsido (remibrutinib)

    Prescription medicine decision summary
    Rhapsido has been approved for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. Rhapsido contains the active ingredient remibrutinib.